The update removes a previous limitation of use that stated that the drug should not be used as the initial therapy.
Initially approved by in the US in 2019, Rybelsus is the first and only analogue of the naturally occurring hormone glucagon-like peptide-1 (GLP-1) in pill form and is indicated, along with diet and exercise, to improve glycemic control for adults with type 2 diabetes.
Rybelsus works differently to other diabetes pills to lower blood sugar by increasing the release of insulin from the pancreas when blood sugar is high, decreasing the release of sugar from the liver, and slowing the process of food leaving the stomach after eating.
